Beyond Air Inc XAIR

Healthcare Medical Devices

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.

NDAQ:XAIR - Post by User

Beyond Air Inc

<< Previous

Bullboard Posts

(199)
•••

Post by Red~Oneon Aug 23, 2022 3:41pm

67 Views

Post# 34915134

phase 1 study

Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy Beyond Air ( NASDAQ: XAIR ) unit Beyond Cancer said on Tuesday the first patient had been treated in a Phase 1 study to assess the safety and immune biomarkers of ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors. The company expects initial clinical data from the trial in early 2023. The study will evaluate the maximum tolerated dose, safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment. The primary endpoints of the early-stage study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities, and changes in safety parameters. ( XAIR ) rose ~4% premarket. For further details see: Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy Source: SeekingAlpha (Aug 23, 2022 09:12:20 EDT) News by QuoteMedia www.quotemedia.com

<< Previous

Bullboard Posts

This stock is ready to capture the lead in the diabetes market